Bausch + Lomb BLCO Branded and Other Generics — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch + Lomb's branded and other generics — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch + Lomb's branded and other generics — total revenues?
- Bausch + Lomb (BLCO) reported branded and other generics — total revenues of $49M in Q1 2026.
- How has Bausch + Lomb's branded and other generics — total revenues changed year-over-year?
- Bausch + Lomb's branded and other generics — total revenues decreased by 9.3% year-over-year, from $54M to $49M.
- What is the long-term trend for Bausch + Lomb's branded and other generics — total revenues?
- Over 4 years (2021 to 2025), Bausch + Lomb's branded and other generics — total revenues has grown at a -1.2% compound annual growth rate (CAGR), from $254M to $242M.
- What does branded and other generics — total revenues mean?
- This metric represents the total net sales generated from the company's portfolio of branded and generic pharmaceutical products within a specific business segment. It reflects the market demand and pricing power for non-proprietary or legacy pharmaceutical offerings that compete in the broader healthcare landscape. Monitoring this revenue stream helps investors assess the stability and contribution of mature product lines to the overall corporate top-line performance.